Mavixen 100 mg + 40 mg (Glecaprevir + Pibrentasvir)

Description

Description

Mavixen 100 mg+40 mg (Tablet)

generic :
Glecaprevir + Pibrentasvir.

It is manufactured by,
Everest Pharmaceuticals Ltd.

Mavixen Tablet

Glecaprevir + Pibrentasvir

100 mg+40 mg

Everest Pharmaceuticals Ltd.

Unit Price: ৳ 4,000.00 (21’s pack: ৳ 84,000.00)

Indications

This is a fixed-dose combination of glecaprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor, and is indicated for the treatment of patients with chronic HCV genotype (GT) 1, 2, 3, 4, 5 or 6 infection without cirrhosis and with compensated cirrhosis (Child-Pugh A). This is also indicated for the treatment of adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both.

Therapeutic Class

Hepatic viral infections (Hepatitis C)

Pharmacology

Glecaprevir is an inhibitor of the HCV NS3/4A protease, which is a viral enzyme necessary for the proteolytic cleavage of the HCV encoded polyprotein into mature forms of the NS3, NS4A, NS4B, NS5A, and NS5B proteins. These multifunctional proteins, including NS3, are essential for viral replication. The N-terminal of NS3 protein confers serine protease activity, whileThe C-terminus of NS3 encodes a DExH/D-box RNA helicase which hydyolyzes NTP as an energy source to unwind double-stranded RNA in a 3′ to 5′ direction during replication of viral genomic RNA. NS4A is a cofactor for NS3 that directs the localization of NS3 and modulates its enzymatic activities. Glecaprevir disrupts the intracellular processes of the viral life cycle through inhibiting the NS3/4A protease activity of cleaving downstream junctions of HCV polypeptide and proteolytic processing of mature structural protein.

#NASIMA_PHARMA.